Last reviewed · How we verify

mOPV2 at 6 and 7 weeks of age

Centers for Disease Control and Prevention · FDA-approved active Biologic

mOPV2 at 6 and 7 weeks of age is a Live attenuated vaccine Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved for Prevention of poliomyelitis caused by poliovirus type 2 in infants.

mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.

mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus type 2 in infants.

At a glance

Generic namemOPV2 at 6 and 7 weeks of age
SponsorCenters for Disease Control and Prevention
Drug classLive attenuated vaccine
TargetPoliovirus type 2
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

mOPV2 contains a weakened (attenuated) form of poliovirus type 2 administered orally. When ingested, the vaccine replicates in the intestinal tract and stimulates both mucosal and systemic immune responses, including antibody production and T-cell immunity against poliovirus type 2. This vaccination at 6 and 7 weeks of age is part of routine childhood immunization schedules to provide early protection against polio.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about mOPV2 at 6 and 7 weeks of age

What is mOPV2 at 6 and 7 weeks of age?

mOPV2 at 6 and 7 weeks of age is a Live attenuated vaccine drug developed by Centers for Disease Control and Prevention, indicated for Prevention of poliomyelitis caused by poliovirus type 2 in infants.

How does mOPV2 at 6 and 7 weeks of age work?

mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.

What is mOPV2 at 6 and 7 weeks of age used for?

mOPV2 at 6 and 7 weeks of age is indicated for Prevention of poliomyelitis caused by poliovirus type 2 in infants.

Who makes mOPV2 at 6 and 7 weeks of age?

mOPV2 at 6 and 7 weeks of age is developed and marketed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).

What drug class is mOPV2 at 6 and 7 weeks of age in?

mOPV2 at 6 and 7 weeks of age belongs to the Live attenuated vaccine class. See all Live attenuated vaccine drugs at /class/live-attenuated-vaccine.

What development phase is mOPV2 at 6 and 7 weeks of age in?

mOPV2 at 6 and 7 weeks of age is FDA-approved (marketed).

What are the side effects of mOPV2 at 6 and 7 weeks of age?

Common side effects of mOPV2 at 6 and 7 weeks of age include Mild fever, Local irritation at injection site (if given as IPV), Vaccine-strain poliovirus shedding in stool.

What does mOPV2 at 6 and 7 weeks of age target?

mOPV2 at 6 and 7 weeks of age targets Poliovirus type 2 and is a Live attenuated vaccine.

Related